pioglitazone has been researched along with Leishmaniasis, Cutaneous in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nascimento, MT | 1 |
| Cordeiro, RSO | 1 |
| Abreu, C | 1 |
| Santos, CP | 1 |
| Peixoto, F | 1 |
| Duarte, GA | 1 |
| Cardoso, T | 1 |
| de Oliveira, CI | 1 |
| Carvalho, EM | 1 |
| Carvalho, LP | 1 |
1 other study available for pioglitazone and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Downregulates the Inflammatory Response in Cutaneous Leishmaniasis Patients Without Interfering in
Topics: Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Monocytes; Pioglitazone; PPAR gamma | 2022 |